Annovis Bio ANVS 深 滬
已收盤 10-24 16:00:00 美东时间
2.05
+0.030
+1.49%
華盛通- 最 高2.07
- 今 開2.05
- 成交量 26.79万股
- 最 低 2.02
- 昨 收 2.02
- 總市值 3994.67万
- 52周最高 9.23
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 1.11
- 委 比 17.65%
- 總股本 1948.62万
- 歷史最高 132.00
- 量 比 0.55
- 振 幅 2.48%
- 歷史最低 1.11
- 每 手 1
- 風險率 2.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Annovis launches $6 million registered direct offering
Annovis Bio (NYSE:ANVS) has entered into definitive agreements for the purchase of an aggregate of 4M shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 p...
10-10 20:58
Annovis Announces $6 Million Registered Direct Offering of Common Stock
Annovis Bio, a late-stage clinical company focused on neurodegenerative diseases, has entered into definitive agreements to purchase 4 million shares of its common stock at $1.50 per share in a registered direct offering, expected to close on October 13, 2025. The offering is being led by H.C. Wainwright & Co. as the exclusive placement agent and is expected to generate approximately $6 million in gross proceeds for the Company, which plans to us...
10-10 12:31
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
<p>Annovis Bio announced new results showing that buntanetap reduces inflammation and improves cellular health in Alzheimer’s patients, potentially modifying the disease. The drug decreased key inflammatory markers and neuronal damage indicators, suggesting its efficacy across disease stages. Buntanetap is currently in Phase 3 trials targeting early AD, with results expected in 6 and 18 months. The findings will be presented at the CTAD conferenc...
10-09 11:30
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
Anavex Life Sciences Corp. has successfully developed a once-daily oral tablet formulation for ANAVEX®3-71, which exhibits superior pharmacokinetics compared to the current immediate-release capsule. A Phase 1b trial (ANAVEX3-71-002) confirmed the tablet's safety, tolerability, and suitability for daily dosing in both male and female adults. ANAVEX®3-71, a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, shows potential to addr...
10-02 11:35
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Canaccord Genuity Maintains Buy on Annovis Bio, Maintains $17 Price Target
Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and maintains $17 price target.
09-30 21:41
Annovis Bio appoints CFO
Clinical drug platform company Annovis Bio (NYSE:ANVS) announced on Thursday the appointment of Mark Guerin as CFO. Guerin has previously served at Onconova Therapeutics (TRAW), now known as Traws Pha...
09-25 19:55
Annovis Appoints Mark Guerin as Chief Financial Officer
Annovis Bio appoints Mark Guerin as CFO to lead the company during a key phase for its neurodegenerative disease therapy buntanetap. Guerin brings extensive biopharma financial experience, including成功领导Onconova Therapeutics的财务运营和多个融资项目。Annovis is focused on advancing innovative treatments for Alzheimer's and Parkinson's diseases.
09-25 11:30
Annovis Bio Highlights New Buntanetap Form In Phase 3 Alzheimer's Trial, Extends Patent Protection Into 2040s
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
09-16 19:38
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
Annovis Bio, Inc. announced the publication of a study in *Biomolecules* detailing the pharmacokinetic profile of a new dihydrate crystal form of buntanetap, used in its late-stage clinical trials for Alzheimer's disease. This new crystal form offers greater stability and maintains the same absorption and clearance as the original anhydrous form, ensuring therapeutic efficacy. Currently in pivotal Phase 3 trials, the new crystal extends the compa...
09-16 11:30
